SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceXs rally is drawing attention to Morgan Stanleys bullish coverage and Musks proposed SpaceXAI-to-SpaceXSI rebrand, alongside strong breakout momentum and speculation about the companys AI potential. Bulls point to continued gains and possible short-covering, while skeptics argue the valuation is stretched and flag share unlocks as a risk.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavaxs sharp rally has traders pointing to reported approvals for its updated Nuvaxovid vaccine and partner-led commercialization, while speculation about a Russian plague outbreak is also fueling vaccine-stock FOMO. Much of the discussion centers on whether the move reflects those developments or short-covering, with claims of an imminent squeeze remaining speculative.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazons reported exploration of moving Nvidia AI chips into an investor-funded vehicle and leasing them back has drawn attention amid debate over its heavy AI infrastructure spending. Some traders view the move as a warning about financing risks and falling chip values, while others see balance-sheet engineering that leaves the chips in use; frustration with AMZNs choppy, underperforming share price is widespread.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

GRRR is drawing attention amid a sharp pullback, with traders focused on uncertainty over financing its AI data-center projects and the risk of further dilution, alongside doubts about management credibility and execution. Bulls cite GPU deployments and contracted growth, while some traders blame broader AI-sector risk-off rather than a company-specific setback.

Applied Optoelectronics, Inc. engages in the design and manufacture of optical communications products. Its products include optical devices, such as laser diodes, photodiodes, related modules and circuitry, and equipment for applications in fiber-to-the-home, cable television, point to point communications, and wireless. The company was founded by Chih Hsiang Lin on February 28, 1997 and is headquartered in Sugar Land, TX.

Applied Optoelectronics Inc

AAOIs rebound is being linked by traders to the reported completion of its at-the-market stock sale, easing dilution concerns and reviving momentum in a photonics sector buoyed by AI and data-center optics demand. The bullish breakout talk remains tempered by doubts that selling has ended and concerns about volatility and profit-taking.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricors 24-month HOPE-3 open-label extension data, including a reported 76% slower upper-limb decline after patients switched to deramiocel, has renewed focus on the therapys FDA review for Duchenne muscular dystrophy. Traders are split: some see the results as supporting approval, while others emphasize statistical concerns and analyst warnings that the FDA could issue a Complete Response Letter; the share-price decline has also prompted unsubstantiated claims of short-driven pressure.

Armada Acquisition Corp. II is a blank check company, which engages in the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combinations with one or more businesses. The company was founded on October 3, 2024 and is headquartered in Miami, FL.

Armada Acquisition Corp. II - Ordinary Shares- Class A

Evernorth Holdings Inc.

Shareholder approval of Evernorths merger with Armada cleared the way for a Nasdaq debut under XRPN, with the company expected to hold a large XRP treasury; traders have piled into the low-float name amid XRP-related enthusiasm and speculation around the listing. The discussion is sharply divided between momentum bulls and traders warning that the stocks surge may outpace the value of its XRP holdings, while others debate warrant exercise and potential dilution.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivians record Q3 deliveries topped expectations as the R2 ramp gained momentum, but the stock drew a sell-the-news reaction after the company reaffirmed rather than raised its full-year guidance. Bulls see volume growth as progress, while bears focus on the unchanged outlook, cash burn and the need to demonstrate a path to profitability.

Vaxcyte, Inc. engages in the development of vaccines for infectious diseases. It focuses on conjugate vaccines and protein-based vaccines developed through the Sutro Biopharma's Xpress CF Platform, a cell-free protein synthesis technology. The company was founded by Grant E. Pickering and Jeff Fairman on November 27, 2013, and is headquartered in San Carlos, CA.

Vaxcyte Inc

Vaxcyte shares are drawing attention after VAX-31 met the primary endpoints in its pivotal Phase 3 adult pneumococcal vaccine trial, strengthening its case against established vaccines. Traders are celebrating the clinical win but debating the sharp moves staying power, with profit-taking and proposed financing offerings raising dilution concerns.

Redwire Corp. engages in the development and provision of space and defense technologies and mission-critical solutions for government, commercial, and civil customers. Its offerings include spacecraft platforms, space infrastructure, avionics, sensors and payloads, power generation systems, radio frequency systems, microgravity research and manufacturing technologies, autonomous systems, optical sensors, and digital engineering solutions. The company was founded in 2020 and is headquartered in Jacksonville, FL.

Redwire Corporation

Redwire Corp

Redwires follow-on Axiom Space contract for two ROSA solar-array wings is drawing attention, with bullish traders viewing it as added commercial-space backlog. The reaction is mixed: many are frustrated that shares fell despite the contract news, attributing the weakness to selling pressure and speculating about ATM-related dilution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Regentis Biomaterials Is Addressing the ‘Short-Term Relief, Long-Term Failure’ Problem in Knee Cartilage Repair

Cartilage repair is intended to do more than simply reduce pain. Ideally, proper treatment should also restore the cartilage tissue responsible for the smooth movement and durability of a healthy joint. Regentis Biomaterials Ltd. (NYSE American: RGNT) is developing a regenerative approach designed to address that challenge&#8230; Read More&#62;&#62; This content was disseminated on behalf [&#8230;]

Regentis Biomaterials and the Shift from Symptom Management to Structural Repair in Knee Cartilage Care

For much of the last three decades, treatment of degenerative knee disease has centered heavily on managing symptoms with anti-inflammatories, activity modification, lubricants and injections, while structural intervention was often reserved for more advanced disease. Focal cartilage defects had surgical options, but those came with their own tradeoffs in durability, complexity, and cost. That balance [&#8230;]

Regentis Biomaterials (NYSE American: RGNT) Advances GelrinC as a Potential New Approach to Knee Cartilage Repair

A knee that once carried a runner through marathons or a hiker up a steep mountainside can be sidelined by a single defect in cartilage. More broadly, nearly a half-million Americans end up with knee cartilage damage each year as a result of long-term wear and tear and every-day accidents. For decades, many available treatments [&#8230;]

Regenerative Hydrogel Is Redefining Cartilage Repair as Regentis Advances GelrinC

Regenerative medicine is increasingly focused on a simple but ambitious goal: rather than simply treating damaged tissue, can medicine help the body rebuild it? One company pursuing a regenerative approach is Regentis Biomaterials Ltd. (NYSE American: RGNT), a regenerative medicine company developing biomaterial-based solutions for… Read More>> This content has been disseminated on behalf of Regentis Biomaterials Ltd. […]

Regentis Biomaterials (NYSE American: RGNT) Moves GelrinC Along Parallel US Clinical and European Commercial Tracks

For development-stage medical technology companies, regulatory approval and commercial revenue often sit years apart. A trial needs to be finished, a submission must clear review, manufacturing has to scale, surgeons must be trained and distribution has to be built. Companies able to run those workstreams in parallel rather than in sequence compress the distance between [&#8230;]

Regentis Biomaterials (NYSE American: RGNT) Builds a Manufacturing and Intellectual Property Powerhouse for the Global Cartilage Repair Market

Aging populations are pushing joint disease higher on the orthopedic agenda, with cartilage damage representing one of the field’s largest unmet needs. Current treatments have demonstrated clinical utility, but they remain difficult to deliver efficiently and economically on scale. That gap is where off-the-shelf therapies can deliver high value, and where manufacturing know-how and intellectual [&#8230;]

Regentis Biomaterials (NYSE American: RGNT) Advances Regenerative Solution for Major Unmet Need in Cartilage Repair

Regentis Biomaterials (NYSE American: RGNT) was featured in a recent article that discussed its efforts to advance GelrinC, a potentially first-in-class, off-the-shelf cartilage regeneration platform, and the company’s broader mission to establish a new standard of care in cartilage repair. “Regentis is developing regenerative biomaterial technology as healthcare shifts toward therapies designed to restore damaged tissue rather […]

Regentis Biomaterials (NYSE American: RGNT) Targets $3B Cartilage Repair Market with Cell-Free Gelrin C

Regentis&#160;Biomaterials (NYSE American: RGNT)&#160;is positioning its Gelrin C hydrogel as a practical regenerative medicine solution for cartilage damage that could help address the substantial clinical and economic burden associated with knee osteoarthritis (“OA”). Gelrin C is a cell-free, off-the-shelf hydrogel administered in a single 10-minute procedure, designed to support cartilage regeneration while avoiding the multiple [&#8230;]

Regentis Biomaterials (NYSE American: RGNT) Builds Commercial and Regulatory Momentum as GelrinC Advances Toward Key Milestones

Cartilage Regeneration Gains Strategic Validation The orthopedic industry is increasingly focused on technologies that can address cartilage damage by promoting tissue regeneration rather than simply managing symptoms. This opportunity gained additional validation when Smith+Nephew completed its acquisition of CartiHeal, a developer of cartilage repair technology, in a transaction valued at up to $330 million. The acquisition demonstrated […]

Regentis Biomaterials (NYSE American: RGNT) Positioned to Benefit as Regenerative Medicine Reshapes the Growing $3B Cartilage Repair Market

Regentis Biomaterials (NYSE American: RGNT)&#160;is developing regenerative biomaterial technology as healthcare shifts toward therapies designed to restore damaged tissue rather than simply manage symptoms. With cartilage defects affecting hundreds of thousands of patients each year and contributing to pain, reduced mobility, and degenerative joint disease, the company is targeting one of orthopedic medicine’s largest unmet [&#8230;]

Regentis Biomaterials Ltd. engages in the development of tissue repair solutions. It focuses on orthopedic treatments through its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue such as inflamed cartilage and bone tissue. The company was founded by Dror Seliktar and Tal Yehiel on September 1, 2004 and is headquartered in Or-Akiva, Israel.

Regentis Biomaterials Ltd.

Why Did RGNT Stock Surge More Than 850% Today?

Equity

Neutral Sentiment

Up more than 1% 

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be this week?

Current Price	$1.67
Prev Close	$1.85
Open	$1.83
Dividend Yield	0.00%
50-Day Moving Average	$1.96
Beta	3.55
Avg. Volume	54,085.63
PE Ratio	-0.75

52-Week High	$15.50
52-Week Low	$1.23
Market Capitalization	$12.99M
EPS (Annual)	-$2.64
Price to Book	1.69
Revenue Per Employee	$0.00

Feed

News

Sentiment

Fundamentals

Info

RGNT Fundamentals